Neil Kumar Bridge Bio Pharma, Inc. (BBIO) insider trading activity

Neil Kumar is Chief Executive Officer of BridgeBio Pharma, Inc.. Currently has a direct ownership of 211,718 shares of BBIO, which is worth approximately $7.17 Million. The most recent transaction as insider was on Feb 16, 2023, when has been sold 68,706 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 212K

0% 3M change

95.65% 12M change

Total Value Held $7.17 Million

Neil Kumar Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 16 2023	BUY Exercise of conversion of derivative security	-	68,706 Added 1.39%	4,881,903 Common Stock
Nov 17 2022	SELL Open market or private sale	$325,616 $9.4 p/Share	34,640 Reduced 0.71%	4,813,197 Common Stock
Nov 16 2022	SELL Payment of exercise price or tax liability	$328,396 $9.64 p/Share	34,066 Reduced 0.7%	4,847,837 Common Stock
Nov 16 2022	BUY Exercise of conversion of derivative security	-	68,706 Added 1.39%	4,881,903 Common Stock
Aug 16 2022	SELL Payment of exercise price or tax liability	$306,883 $11.08 p/Share	27,697 Reduced 0.57%	4,813,197 Common Stock
Aug 16 2022	BUY Exercise of conversion of derivative security	-	68,705 Added 1.4%	4,840,894 Common Stock
May 16 2022	SELL Payment of exercise price or tax liability	$160,136 $6.74 p/Share	23,759 Reduced 0.5%	4,772,189 Common Stock
May 16 2022	BUY Exercise of conversion of derivative security	-	68,705 Added 1.41%	4,795,948 Common Stock
Feb 16 2022	SELL Payment of exercise price or tax liability	$27,271 $8.84 p/Share	3,085 Reduced 0.07%	4,727,243 Common Stock
Feb 16 2022	BUY Exercise of conversion of derivative security	-	7,524 Added 0.16%	4,730,328 Common Stock
Nov 16 2021	SELL Payment of exercise price or tax liability	$176,242 $47.25 p/Share	3,730 Reduced 0.08%	4,722,804 Common Stock
Nov 16 2021	BUY Exercise of conversion of derivative security	-	7,523 Added 0.16%	4,726,534 Common Stock
Aug 16 2021	SELL Payment of exercise price or tax liability	$184,560 $49.48 p/Share	3,730 Reduced 0.08%	4,719,011 Common Stock
Aug 16 2021	BUY Exercise of conversion of derivative security	-	7,523 Added 0.16%	4,722,741 Common Stock
May 16 2021	SELL Payment of exercise price or tax liability	$200,205 $53.66 p/Share	3,731 Reduced 0.08%	4,715,218 Common Stock
May 16 2021	BUY Exercise of conversion of derivative security	-	7,524 Added 0.16%	4,718,949 Common Stock
Feb 17 2021	BUY Payment of exercise price or tax liability	$1,000,000 $62.5 p/Share	16,000 Added 0.34%	4,711,425 Common Stock
Feb 16 2021	SELL Payment of exercise price or tax liability	$138,992 $64.98 p/Share	2,139 Reduced 0.05%	4,695,425 Common Stock
Feb 16 2021	BUY Exercise of conversion of derivative security	-	5,129 Added 0.11%	4,697,564 Common Stock
Nov 16 2020	SELL Payment of exercise price or tax liability	$78,641 $44.33 p/Share	1,774 Reduced 0.04%	4,692,435 Common Stock
Nov 16 2020	BUY Exercise of conversion of derivative security	-	5,129 Added 0.11%	4,694,209 Common Stock

Neil Kumar

Chief Executive Officer

Palo Alto, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BBIO shares.

Notify only if

Value

Insider Trading

Get notified when an Bridge Bio Pharma, Inc. insider buys or sells BBIO shares.

Notify only if

Operation

Value

Type

News

Receive news related to BridgeBio Pharma, Inc.

Track Activities on BBIO

Account